<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2415">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611256</url>
  </required_header>
  <id_info>
    <org_study_id>060I.2020</org_study_id>
    <nct_id>NCT04611256</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells in Patients Diagnosed With COVID-19</brief_title>
  <official_title>Adjuvant Therapy With Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 in Critical Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Reg. Lic. Adolfo Lopez Mateos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Terapia Celular: ITC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Reg. Lic. Adolfo Lopez Mateos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The propose of this study is implement adjuvant therapy with adipose tissue&#xD;
      derived-mesenchymal stem cells (MSCs) for critical COVID-19 patients admitted to the&#xD;
      intensive care unit of the Regional Hospital Lic. Adolfo López Mateos of the Institute for&#xD;
      Social Security and Services for State Workers to reduce cytokine storm and contribute to the&#xD;
      favorable resolution of respiratory insufficiency and multiple organic failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within the epidemic context of phase 3 that currently exists in Mexico, implementation of new&#xD;
      treatments that have shown to be beneficial for patients in a critical state in other&#xD;
      countries is an urgent need. Adipose tissue derived-mesenchymal stem cells for could favor&#xD;
      the regulation of patient immune system to reduce the proinflammatory state and promoting the&#xD;
      regeneration of damaged tissues.&#xD;
&#xD;
      Patients diagnosed COVID-19 and confirmed positive with the virus by PCR, will be treated&#xD;
      with two intravenous infusions MSCs on the day 1 (D1) and the day 3 (D3) of the treatment&#xD;
      consisting of 1X106/kg each.&#xD;
&#xD;
      We will assess the pulmonary lesion area by chest x-ray or computed axial tomography at&#xD;
      baseline and days 2, 3, 5, 10, 15, 20, and 25.&#xD;
&#xD;
      Days to clinical improvement (to be evaluated on days 2, 3, 5, 10, 15, 20, 25), considering&#xD;
      temperature and other vital signs measurement, arterial oxygen saturation, blood chemistry&#xD;
      (including liver function tests), creatine phosphokinase, C reactive protein, immune cells&#xD;
      (CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes), pro-inflammatory cytokines (IL-1β,&#xD;
      IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10), immunoglobulins (IgA, IgG, IgM, and IgE), HLA&#xD;
      profile expression, and weaning from mechanical ventilation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change form baseline in Arterial oxygen saturation</measure>
    <time_frame>up to 25 days</time_frame>
    <description>Pulmonary lesion area will be taken by a chest x-ray or computed axial tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change form baseline in Arterial oxygen saturation</measure>
    <time_frame>up to 25 days</time_frame>
    <description>Aretrial oxygen saturation will be taken by an oximeter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days to clinical improvement</measure>
    <time_frame>up to 25 days</time_frame>
    <description>Number of days of patient discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Form Baseline in C reactive protein at 25 days</measure>
    <time_frame>up to 25 days</time_frame>
    <description>Blood samples will be taken on days 1, 3, 7, 15, 20, 25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Form Baseline Immune cells: CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes</measure>
    <time_frame>up to 25 days</time_frame>
    <description>Blood samples will be taken on days 1, 3, 7, 15, 20, 25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Form Baseline in pro-inflammatory cytokines: IL-1β, IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10</measure>
    <time_frame>up to 25 days</time_frame>
    <description>Blood samples will be taken on days 1, 3, 7, 15, 20, 25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Form Baseline in Immunoglobulins; IgA, IgG, IgM, and IgE.</measure>
    <time_frame>up to 25 days</time_frame>
    <description>Blood samples will be taken on days 1, 3, 7, 15, 20, 25</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>MSC transfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC</intervention_name>
    <description>Two intravenous infusion of 1*10E6 adipose tissue derived-MSCs /kg body weight reach</description>
    <arm_group_label>MSC transfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18 and 65.&#xD;
&#xD;
          -  RT-PCR positive for SARS-CoV-2 (Berlin protocol).&#xD;
&#xD;
          -  Moderate to severe acute respiratory insufficiency (100 mmHg &lt;PaO2/FiO2 ≤ 200 mmHg).&#xD;
&#xD;
          -  Confirmatory diagnosis of pulmonary injury by chest teleradiography or computed axial&#xD;
             t tomography.&#xD;
&#xD;
          -  Being under standard therapy for COVID-19.&#xD;
&#xD;
          -  Informed consent signed by the patient or a legally acceptable representative (in the&#xD;
             case of the legal representative, informed consent could be obtained by a phone call&#xD;
             or email with the subsequent written confirmation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reserved prognosis (survival expected by the physician of fewer than three days).&#xD;
&#xD;
          -  Being under immunosuppressive drug treatment.&#xD;
&#xD;
          -  Severe kidney failure (estimated glomerular filtration rate &lt; 30 ml/min) or under&#xD;
             continuous kidney replacement therapy, hemodialysis, or peritoneal dialysis.&#xD;
&#xD;
          -  Immunosuppressed patients (except when the cause is corticosteroid treatment).&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients who plan to become pregnant during the study period or within six months&#xD;
             after the end of the study period.&#xD;
&#xD;
          -  Participation in another clinical trial with an experimental drug during the last 30&#xD;
             days.&#xD;
&#xD;
          -  Pathologies that in medical judgment constitute a contraindication to participate in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Regional Lic Adolfo Lopez Mateos</name>
      <address>
        <city>Mexico City</city>
        <state>Ciudad De Mexico CDMX (Mexico City)</state>
        <zip>01030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha E. Rodríguez Arellano, MD</last_name>
      <phone>+52 5512999131</phone>
      <email>marthaeunicer@yahoo.com.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Reg. Lic. Adolfo Lopez Mateos</investigator_affiliation>
    <investigator_full_name>M. Eunice Rodríguez Arellano</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Adjuvant therapy</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>Mexico</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

